X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (36) 36
oncology (32) 32
humans (29) 29
hematology (26) 26
male (22) 22
middle aged (22) 22
female (21) 21
aged (20) 20
multiple myeloma (18) 18
adult (15) 15
aged, 80 and over (15) 15
dexamethasone (15) 15
care and treatment (13) 13
patients (13) 13
multiple myeloma - drug therapy (12) 12
cancer (10) 10
treatment outcome (10) 10
toxicity (9) 9
abridged index medicus (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
bortezomib (8) 8
drug dosages (8) 8
transplantation (8) 8
analysis (7) 7
lenalidomide (7) 7
open-label (7) 7
safety (7) 7
survival (7) 7
carfilzomib (6) 6
clinical trials (6) 6
dexamethasone - administration & dosage (6) 6
disease-free survival (6) 6
efficacy (6) 6
hematology, oncology and palliative medicine (6) 6
maximum tolerated dose (6) 6
multiple myeloma - mortality (6) 6
neutropenia (6) 6
therapy (6) 6
administration, oral (5) 5
antibodies, monoclonal - therapeutic use (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
chronic lymphocytic-leukemia (5) 5
diseases (5) 5
drug administration schedule (5) 5
immunology (5) 5
leukemia (5) 5
lymphoma (5) 5
lymphomas (5) 5
myelodysplastic syndromes (5) 5
non-hodgkins-lymphoma (5) 5
pharmacokinetics (5) 5
prognosis (5) 5
pyrimidines - administration & dosage (5) 5
pyrimidines - adverse effects (5) 5
recurrence (5) 5
relapse (5) 5
rituximab (5) 5
stem cells (5) 5
steroids (5) 5
thrombocytopenia (5) 5
acute myeloid-leukemia (4) 4
antineoplastic agents - administration & dosage (4) 4
bone marrow (4) 4
cancer therapies (4) 4
clinical trials and observations (4) 4
cyclophosphamide (4) 4
dexamethasone - adverse effects (4) 4
dose-response relationship, drug (4) 4
drug therapy (4) 4
ixazomib (4) 4
kaplan-meier estimate (4) 4
medical research (4) 4
medicine, experimental (4) 4
multiple myeloma - pathology (4) 4
myelodysplastic syndrome (4) 4
neoplasm staging (4) 4
survival rate (4) 4
trial (4) 4
anemia (3) 3
antibodies, monoclonal - administration & dosage (3) 3
antineoplastic agents - therapeutic use (3) 3
apoptosis (3) 3
article (3) 3
azacitidine - administration & dosage (3) 3
azacitidine - adverse effects (3) 3
chemotherapy (3) 3
combination (3) 3
complications and side effects (3) 3
decitabine (3) 3
failure (3) 3
fatigue (3) 3
fda approval (3) 3
follow-up (3) 3
glycine - analogs & derivatives (3) 3
haematological malignancy (3) 3
immunomodulation (3) 3
immunotherapy (3) 3
infusions, intravenous (3) 3
leukemia, lymphocytic, chronic, b-cell - drug therapy (3) 3
lymphoma, non-hodgkin - drug therapy (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Oncologist, ISSN 1083-7159, 08/2019, Volume 24, Issue 8, pp. 1035 - e623
经验总结 • 在老年弥漫大 B 细胞淋巴瘤患者中,苯达莫司汀联合奥法单抗与标准治疗相比疗效有限。 • 有效率低的原因可能是患者年龄与治疗终止率高的影响。 摘要 背景。 本项 II 期试验评估了苯达莫司汀联合奥法单抗在初诊老年弥漫大 B 细胞淋巴瘤 (DLBCL) 而不适合利妥昔单抗、环磷酰胺、阿霉素、长春新碱和泼尼松... 
TRIAL | MULTICENTER | MONOTHERAPY | ONCOLOGY | RITUXIMAB | OLDER | COMBINATION | Index Medicus | Clinical Trial Results
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 03/2018, Volume 24, Issue 3, p. S259
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 05/2019
The oral proteasome inhibitor oprozomib has shown preclinical antitumor activity. Here, we report phase 1b/2 study results investigating single-agent oprozomib... 
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 03/2018, Volume 24, Issue 3, pp. S259 - S259
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 13, pp. 1503 - 1512
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 11, pp. 1569 - 1578
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 622 - 631
Journal Article
American Journal of Hematology, ISSN 0361-8609, 04/2016, Volume 91, Issue 4, pp. 400 - 405
The PI3K/AKT/mTOR signaling pathways are frequently dysregulated in multiple human cancers, including multiple myeloma (MM), non‐Hodgkin lymphoma (NHL), and... 
MAMMALIAN TARGET | RAPAMYCIN | INTERNATIONAL WORKSHOP | MTOR INHIBITION | RESPONSE CRITERIA | EVEROLIMUS | KINASE | PATIENTS PTS | HEMATOLOGY | CANCER | PI3K INHIBITOR | Benzoxazoles - pharmacology | Recurrence | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Mechanistic Target of Rapamycin Complex 2 | Mechanistic Target of Rapamycin Complex 1 | Multiprotein Complexes - antagonists & inhibitors | TOR Serine-Threonine Kinases - antagonists & inhibitors | Multiple Myeloma - drug therapy | Neoplasm Grading | Waldenstrom Macroglobulinemia - drug therapy | Aged, 80 and over | Female | Antineoplastic Agents - pharmacology | Waldenstrom Macroglobulinemia - diagnosis | Lymphoma, Non-Hodgkin - drug therapy | Multiple Myeloma - diagnosis | Administration, Oral | Benzoxazoles - therapeutic use | Treatment Outcome | Pyrimidines - pharmacology | Retreatment | Maximum Tolerated Dose | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Aged | Protein Kinase Inhibitors - pharmacology | Drug Monitoring | Neoplasm Staging | Lymphoma, Non-Hodgkin - diagnosis | Medical research | Care and treatment | Relapse | Plasma physics | Multiple myeloma | Clinical trials | Medicine, Experimental | Lymphomas | Nausea | Diseases | TOR protein | Thrombocytopenia | Creatinine | Toxicity | Urticaria | Mucosa | Fatigue | AKT protein | Patients | Lymphoma | 1-Phosphatidylinositol 3-kinase | Stomatitis | Asthenia | Vomiting | Pharmacokinetics | Drug dosages | Hodgkin's disease | Neutropenia | Macroglobulinemia | Index Medicus
Journal Article
The Lancet Oncology, ISSN 1470-2045, 10/2017, Volume 18, Issue 10, pp. 1317 - 1326
Journal Article
Cancer, ISSN 0008-543X, 03/2017, Volume 123, Issue 6, pp. 994 - 1002
Journal Article
British journal of haematology, 11/2017
This Phase II trial evaluated the efficacy of bendamustine, bortezomib and rituximab in patients with previously untreated low-grade lymphoma. Eligible... 
Journal Article
British Journal of Haematology, ISSN 0007-1048, 07/2018, Volume 182, Issue 2, pp. 231 - 244
Weekly ixazomib with lenalidomide‐dexamethasone (Rd) is feasible and has shown activity in newly diagnosed multiple myeloma ( NDMM ) patients. This phase 1/2... 
newly diagnosed | multiple myeloma | oral | ixazomib | twice‐weekly | twice-weekly | BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE | PROTEASOME INHIBITOR IXAZOMIB | CYCLOPHOSPHAMIDE | AUTOLOGOUS TRANSPLANTATION | OPEN-LABEL | MAINTENANCE THERAPY | CARFILZOMIB | CONSOLIDATION THERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | LOW-DOSE DEXAMETHASONE | Glycine - analogs & derivatives | Glycine - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Boron Compounds - administration & dosage | Dose-Response Relationship, Drug | Multiple Myeloma - drug therapy | Aged, 80 and over | Lenalidomide - pharmacokinetics | Adult | Female | Glycine - administration & dosage | Glycine - pharmacokinetics | Dexamethasone - administration & dosage | Drug Administration Schedule | Administration, Oral | Boron Compounds - pharmacokinetics | Treatment Outcome | Dexamethasone - pharmacokinetics | Disease-Free Survival | Lenalidomide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lenalidomide - adverse effects | Boron Compounds - adverse effects | Aged | Complications and side effects | Medical research | Care and treatment | Hyperglycemia | Dexamethasone | Multiple myeloma | Medicine, Experimental | Steroids | Toxicity | Pharmacology | Pharmacokinetics | Peripheral neuropathy | Patients | Drug dosages | Index Medicus | Haematological Malignancy | Research Paper
Journal Article